AO 120 (Rev. 08/10)

TO:	Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court for the District of Delaware on the following

☐ Trademarks or ☑ Patents. (☐ the patent action involves 35 U.S.C. § 292.):

DOCKET NO. 15-986	DATE FILED 10/28/2015	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG		DEFENDANT AMNEAL PHARMACEUTICALS LLC

PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 6,894,051	5/17/2005	Novartis AG
2 RE43,932	1/15/2013	Novartis AG
3		
4		
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY ☐ Amendment ☐ Answer ☐ Cross Bill ☐ Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

Stipulation of Dismissal

CLERK	(BY) DEPUTY CLERK	DATE
John A. Cerino		1-24-2017

Copy 1—Upon initiation of action, mail this copy to Director **Copy 3—Upon termination of action, mail this copy to Director**
Copy 2—Upon filing document adding patent(s), mail this copy to Director **Copy 4—Case file copy**

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG,	)	
Plaintiffs,	)	Civil Action No. 15-986-LPS
v.	)	
AMNEAL PHARMACEUTICALS, LLC,	)	
Defendant.	)	

STIPULATION AND [PROPOSED] ORDER OF DISMISSAL WITHOUT PREJUDICE UNDER FEDERAL RULE OF CIVIL PROCEDURE 41(a)(2)

WHEREAS, Plaintiffs Novartis Pharmaceuticals Corporation and Novartis AG (together, "Novartis") and Defendant, Amneal Pharmaceuticals, LLC ("Amneal") are parties in the above-captioned proceeding;

IT IS HEREBY STIPULATED AND AGREED by the parties to the above-captioned action, by and through their undersigned counsel, and subject to the approval of the Court, that pursuant to Federal Rule of Civil Procedure 41(a)(2), the above-captioned action, including all claims, counterclaims, and affirmative defenses asserted by the parties against one another, is hereby dismissed in its entirety without prejudice, with each party to bear its own costs and attorneys' fees in this action.

Dated: January 18, 2017

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver
Michael P. Kelly (No. 2295)
Daniel M. Silver (No. 4758)
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, Delaware 19801
(302) 984-6300
mkelly@mccarter.com
dsilver@mccarter.com

Attorneys for Plaintiffs Novartis Pharmaceuticals Corporation and Novartis AG

OF COUNSEL:

David K. Barr
ARNOLD & PORTER
KAYE SCHOLER LLP
250 West 55th Street
New York, New York 10019
(212) 836-8000
david.barr@apks.com

YOUNG CONAWAY STARGATT & TAYLOR, LLP

/s/ Anne Shea Gaza
Anne Shea Gaza (No. 4093)
Robert M. Vrana (No. 5666)
Rodney Square
1000 North King Street
Wilmington, Delaware 19801
Tel: (302) 571-6600
agaza@ycst.com
rvrana@ycst.com

Attorneys for Defendant Amneal Pharmaceuticals LLC

OF COUNSEL:

Michael H. Imbacuan
BUDD LARNER, P.C.
150 John F. Kennedy Parkway
Short Hills, New Jersey
Tel: (973) 379-4800
mimbacuan@buddlarner.com

SO ORDERED:

United States District Judge

Dated: January 23, 2017
Wilmington, Delaware